Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

May 31, 2016

Conditions
Multiple Myeloma
Interventions
DRUG

Vorinostat, Lenalinomide and Dexamethasone

"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~\* Lenalidomide dose for patients with renal impairment (CrCL\<50ml/min) has be dose adjusted according to package insert~Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"

Trial Locations (1)

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Hackensack Meridian Health

OTHER

NCT01502085 - Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens | Biotech Hunter | Biotech Hunter